Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 7:16:603-609.
doi: 10.2147/OPTH.S352152. eCollection 2022.

Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema

Thi Ha Chau Tran  1 , Stephane Verdun  2 , Jean François Le Rouic  3 , Joel Uzzan  4 , Solange Milazzo #  5 , Laurent Kodjikian  6 , Ali Erginay  7
Affiliations

Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema

Thi Ha Chau Tran et al. Clin Ophthalmol. .

Abstract

Purpose: To evaluate the efficacy of intravitreal aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at two years.

Methods: This is a prospective, non-comparative, multicenter observational study including diabetic patients with visual acuity between 20/400 to 20/40 due to DME, who have undergone vitrectomy at least 3 months before the first aflibercept injection. Treatment protocol included 5 monthly aflibercept injection followed by a ProReNata regimen during the first year. Participants were managed at clinicians' discretion using Treat and Extend or Observe and Plan regimen during the second year. Visual acuity, OCT findings and number of IAI were assessed at two years.

Results: Available data for 28 eyes with DME previously vitrectomized treated with aflibercept intravitreal injection during at least 2 years were collected. Visual gain was +5.4 letters (p = 0.01), and central macular thickness decreased significantly -62µm, p < 0.001) at 2 years. Resolution of macular edema allowing discontinuation of aflibercept was observed in 7 eyes (15%). Mean number of injections was 14.6, and mean interval injection was 6.4 weeks for 2 years.

Conclusion: These results suggest that IAI is beneficial in vitrectomized eyes leading to improvement of visual and anatomical outcome which was maintained for 2 years.

Keywords: aflibercept; anti-VEGF; diabetic macular edema; vitrectomy.

PubMed Disclaimer

Conflict of interest statement

Prof. Dr. Thi Ha Chau Tran reports grants from Bayer Healthcare, during the conduct of the study. Dr Joel Uzzan reports personal fees from Bayer, Allergan, Novartis, and Horus, outside the submitted work. Prof. Dr. Laurent Kodjikian reports personal fees from AbbVie, Novartis, Bayer, and Roche, outside the submitted work. Dr Ali Erginay reports grants from Allergan, Bayer, and Novartis, during the conduct of the study. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow chart from inclusion to 2 years.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tranos PG, Wickremasinghe S, Stangos N, et al. Macular edema. Surv Ophthalmol. 2004;49:470–490. doi:10.1016/S0039-6257(04)00109-2 - DOI - PubMed
    1. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185–222. doi:10.1159/000458539 - DOI - PubMed
    1. Do DV, Nguyen QD, Vitti R, et al. Intravitreal aflibercept injection in diabetic macular edema patients with and without prior anti-vascular endothelial growth factor treatment: outcomes from the Phase 3 program. Ophthalmology. 2016;123:850–857. doi:10.1016/j.ophtha.2015.11.008 - DOI - PubMed
    1. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247–2254. doi:10.1016/j.ophtha.2014.05.006 - DOI - PubMed
    1. Heier JS, Bressler NM, Avery RL, et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol. 2016;134:95–99. doi:10.1001/jamaophthalmol.2015.4110 - DOI - PubMed